Learn more
  • Email icon
Selvita
  • About us
  • Drug Discovery
      • Discovery Areas
        • Integrated Drug Discovery
          • AI-driven Drug Discovery
        • Structural Biology
          • Crystallography
          • Fast-track crystallization
          • Crystallization screening service
        • Recombinant protein production
          • Membrane protein production
          • QC studies of recombinant proteins
        • Assay Development & Screening
          • HTS
          • HCS
          • Biophysical Platform
          • Fragment-Based Drug Discovery
          • Libraries
        • ADME/DMPK
      • HIDDEN
        • Chemistry
          • CADD
          • Medicinal & Synthetic Chemistry
          • Scale-up
          • Analytical Chemistry
          • Solid State Chemistry
          • Selvita’s experience with different chemotypes
        • In vitro Pharmacology
        • In vivo Pharmacology
        • Toxicology
        • Translational Research
      • Therapeutic areas
        • Oncology
        • Infectious diseases
        • Inflammation
        • Fibrosis
        • Neurosciences
        • Respiratory
  • Drug Development
      • Small Molecules
        • Method development, validation, and transfer
        • Raw materials and APIs quality control
        • cGMP Batch release testing
        • ICH Stability Testing and Storage
        • Elemental impurities determination according to ICH Q3D
        • Pharmaceutical impurities identification, determination and testing
        • Nitrosamines determination and testing
        • Pyrrolizidine alkaloids (PAs) determination and testing
        • Cleaning validation
        • Bioequivalence studies
        • Equipment
      • Biologics
        • Method development, validation and transfer
        • Quality control of drug substances, excipients, and drug products
        • cGMP Batch release testing
        • Analytical support in Formulation Development
        • Analytical support for the biosimilars registration process
        • ICH Q6B Testing
        • Physicochemical properties determination
        • Binding properties and potency assays
        • Process- and product-related impurities determination
        • Selvita’s experience in working with growth factors, hormones, and mAbs
        • Equipment
      • R&D
        • Agrochemistry analytical support
        • Flavours and Fragrances
        • Selvita’s experience with different chemotypes
        • Sample submission requirements
  • Our science
      • Blog
      • Scientific resources
      • Webinars & videos
  • Investors & Media
      • News
      • Reports
      • Financial Results
      • Shareholder Structure
      • Corporate information
  • Careers
  • Contact
  • Europen Union flag
  • PL
Expression of Wingless-related integration site-3α (Wnt-3α) and Olfactomedin4 (OLFM4) in pseudopyloric metaplasia of small intestine in patients with Crohn disease
https://selvita.com/wp-content/themes/selvita-theme/skin/assets/images/
Home Expression of Wingless-related integration site-3α (Wnt-3α) and Olfactomedin4 (OLFM4) in pseudopyloric metaplasia of small intestine in patients with Crohn disease

Ready to partner with us?

Get started
Logo Selvita
Drug discovery Drug Development Therapeutic areas
Blog Webinar & videos News Events
About us Investors & Media Careers Contact
  • © Copyright 2023 by Selvita
  • Cookies & Privacy policy
  • Terms & Conditions

Contact us

[email protected] [email protected]

Follow Us